Show simple item record

dc.contributor.authorBaildam, Andrew D
dc.contributor.authorZaloudik, J
dc.contributor.authorHowell, Anthony
dc.contributor.authorBarnes, Diana M
dc.contributor.authorMoore, Michael
dc.contributor.authorSellwood, R A
dc.date.accessioned2010-10-20T11:15:26Z
dc.date.available2010-10-20T11:15:26Z
dc.date.issued1987-05
dc.identifier.citationEffect of tamoxifen upon cell DNA analysis by flow cytometry in primary carcinoma of the breast. 1987, 55 (5):561-6 Br. J. Canceren
dc.identifier.issn0007-0920
dc.identifier.pmid3606948
dc.identifier.urihttp://hdl.handle.net/10541/113549
dc.description.abstractThe effect of tamoxifen upon cellular DNA ploidy in carcinoma of the breast was assessed by flow cytometry (FCM), in a prospective group of 77 patients with primary operable disease. Each had a needle biopsy at the outpatient visit for diagnosis and FCM analysis, and definitive surgery was performed a median of 8 days later. Forty received tamoxifen during this period - 40 mg qds loading dose for 24 h, followed by 20 mg daily until the day of operation: 37 patients received no therapy. The DNA histogram from the needle biopsy was compared with that obtained from the resected tumour for each individual. There was little change between the pair of histograms from tumours from the untreated patients. In those who had received tamoxifen the most consistent effect was a marked reduction in the magnitude of the 'tetraploid' peak in tetraploid or near-tetraploid tumours with DNA indices 1.8-2.0. There was little change in diploid or 'other DNA-aneuploid' tumours. In tetraploid tumours (DNA index of 2.0) the percentage of nuclei in the diploid S phase was significantly related to the percentage of nuclei in the diploid G2 + M/tetraploid G1 peak (P less than 0.003, unpaired t test). These data suggest that an effect of tamoxifen can be demonstrated by FCM upon tumours exhibiting a tetraploid or near-tetraploid DNA content. It is possible that tetraploid or near-tetraploid human mammary tumours may be a distinct group of endocrine responsive tumours within the overall group of aneuploid tumours, and that the majority are probably derived from the diploid population rather than being a true aneuploid population.
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectCancer DNAen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshBreast Neoplasms
dc.subject.meshDNA, Neoplasm
dc.subject.meshFemale
dc.subject.meshFlow Cytometry
dc.subject.meshHumans
dc.subject.meshInterphase
dc.subject.meshMiddle Aged
dc.subject.meshPloidies
dc.subject.meshReceptors, Progesterone
dc.subject.meshTamoxifen
dc.titleEffect of tamoxifen upon cell DNA analysis by flow cytometry in primary carcinoma of the breast.en
dc.typeArticleen
dc.identifier.journalBritish Journal of Canceren
html.description.abstractThe effect of tamoxifen upon cellular DNA ploidy in carcinoma of the breast was assessed by flow cytometry (FCM), in a prospective group of 77 patients with primary operable disease. Each had a needle biopsy at the outpatient visit for diagnosis and FCM analysis, and definitive surgery was performed a median of 8 days later. Forty received tamoxifen during this period - 40 mg qds loading dose for 24 h, followed by 20 mg daily until the day of operation: 37 patients received no therapy. The DNA histogram from the needle biopsy was compared with that obtained from the resected tumour for each individual. There was little change between the pair of histograms from tumours from the untreated patients. In those who had received tamoxifen the most consistent effect was a marked reduction in the magnitude of the 'tetraploid' peak in tetraploid or near-tetraploid tumours with DNA indices 1.8-2.0. There was little change in diploid or 'other DNA-aneuploid' tumours. In tetraploid tumours (DNA index of 2.0) the percentage of nuclei in the diploid S phase was significantly related to the percentage of nuclei in the diploid G2 + M/tetraploid G1 peak (P less than 0.003, unpaired t test). These data suggest that an effect of tamoxifen can be demonstrated by FCM upon tumours exhibiting a tetraploid or near-tetraploid DNA content. It is possible that tetraploid or near-tetraploid human mammary tumours may be a distinct group of endocrine responsive tumours within the overall group of aneuploid tumours, and that the majority are probably derived from the diploid population rather than being a true aneuploid population.


This item appears in the following Collection(s)

Show simple item record